Company Overview
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Why Investors Should Care
Generates a return on equity of 72.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 33.5%.
Revenue has grown at a 39.1% CAGR over the past five years.
Trades at a P/E of 3.7, below the sector median of 24.8.
Maintains a net profit margin of 62.9%.
Carries low leverage with a debt-to-equity ratio of 0.05.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR 39.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 39.14% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +545.86% |
| 6 Months: | +129.22% |
| 3 Months: | -2.83% |
| 1 Month: | -25.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)27.88 · Oversold
P/E of 3.72 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 72.1%.
- Healthy ROCE of 33.5%.
- Excellent profit margin of 62.9%.
- Compounding revenue at 39.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 45.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QTTB Q32 Bio Inc. PHARMA | 11.69 | 3.72 | $348.01M | 0.00% | 33.52% | 72.14% | 39.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.13M | 1.40M | 1.60M | 270.00K | 392.00K | 441.00K | 588.00K | 567.00K | 567.00K | 29.30M | 2.19M | 1.68M | 802.00K | 802.00K | 802.00K | 802.00K | 354.00K | 0 | - | - | - | - | 0 | 0 | 0 | 53.74M | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.23M | 9.17M | 7.58M | 7.86M | 7.72M | - |
| Operating Income | -4.69M | -6.04M | -6.66M | -10.70M | -13.42M | -15.63M | -25.12M | -27.97M | -31.29M | -36.49M | -35.70M | -28.27M | -1.11M | -30.55M | -30.66M | -37.62M | -28.31M | -32.86M | -7.37M | -7.28M | -7.80M | -14.84M | -17.92M | -18.81M | - | -12.23M | -9.17M | -7.58M | 45.88M | -7.72M | -9.12M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.11M | -9.10M | -7.00M | 58.02M | -7.63M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 300.00K | 300.00K | 300.00K | 200.00K | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.03M | -9.49M | -7.39M | 57.73M | -7.61M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.00K | 0 | 0 | - | - | - | - |
| Net Income | -5.55M | -6.00M | -6.53M | -10.22M | -12.43M | -14.15M | -23.85M | -26.27M | -29.63M | -35.33M | -35.34M | -28.23M | -1.07M | -30.50M | -30.61M | 92.11M | -29.09M | -33.73M | -6.84M | -5.81M | -14.03M | 1.03M | -16.98M | -17.59M | - | -11.03M | -9.49M | -7.39M | 57.73M | -7.61M | -8.95M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.02 | -0.54 | -0.54 | 1.59 | -0.51 | -0.59 | -19.84 | -16.69 | -40.52 | -6.33 | -1.42 | -1.46 | - | -0.90 | -0.78 | -0.60 | - | -0.54 | -0.44 |
| R&D Expense | 2.80M | 4.06M | 4.95M | 8.00M | 10.29M | 13.39M | 20.54M | 22.83M | 25.69M | 29.31M | 27.47M | 20.42M | 21.75M | 23.70M | 23.99M | 24.27M | 21.07M | 25.85M | 7.91M | 8.02M | 7.46M | 9.84M | 13.41M | 14.35M | - | 7.12M | 5.16M | 3.56M | - | 3.22M | 4.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 5.32M | 1.67M | 2.70M | 33.97M | 6.65M | -6.65M | 0 | 53.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 45.88M | 41.60M | 66.10M | 36.84M |
| Operating Income | -29.66M | -59.93M | -109.94M | -130.26M | -95.95M | -39.23M | -48.26M | -66.10M | 16.90M |
| EBITDA | - | - | - | - | - | -38.85M | -47.76M | -44.50M | 31.31M |
| Interest Expense | - | - | - | - | - | - | - | 1.10M | 1.10M |
| Pretax Income | - | - | - | - | - | -42.75M | -53.42M | -46.09M | 29.82M |
| Tax Provision | - | - | - | - | - | 62.00K | 318.00K | 21.00K | 0 |
| Net Income | -29.99M | -55.58M | -103.92M | -128.69M | -95.76M | -42.81M | -53.74M | -47.73M | 29.82M |
| Diluted EPS | - | - | - | - | -1.73 | -3.59 | -4.51 | -6.58 | 2.42 |
| R&D Expense | 21.38M | 47.95M | 89.40M | 100.39M | 93.08M | 98.35M | 31.73M | 48.14M | 19.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 137.53M | 259.09M | 310.57M | 263.74M | - | 61.77M | 47.06M | 92.33M | 61.78M |
| Current Assets | - | - | - | - | - | - | 46.85M | 28.72M | 81.88M | 55.05M |
| Cash & Equivalents | 11.39M | 51.58M | 38.22M | 53.77M | 217.43M | - | 43.89M | 25.62M | 77.97M | 48.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 1.06M | 755.00K | 555.00K | 5.39M |
| Total Liabilities | - | 39.22M | 62.74M | 52.06M | 67.74M | - | 192.49M | 229.98M | 86.66M | 19.76M |
| Current Liabilities | - | 8.86M | 22.52M | 12.37M | 22.66M | - | 57.87M | 14.11M | 16.46M | 11.35M |
| Long Term Debt | - | - | - | - | - | - | 5.07M | 43.18M | 9.56M | 3.47M |
| Total Debt | - | - | - | - | - | - | 44.73M | 50.84M | 18.90M | 15.34M |
| Total Equity | -9.89M | -39.45M | 196.35M | 258.51M | 196.00M | - | -130.71M | -182.92M | 5.67M | 42.01M |
| Shares Outstanding | - | - | - | - | - | - | 11.93M | 11.93M | 12.20M | 12.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 6.48M | -42.56M | -91.36M | -94.33M | - | -10.96M | -18.68M | -67.72M | -33.54M |
| Investing Cash Flow | -81.53M | -121.79M | -51.80M | 204.90M | - | -2.47M | -5.00K | 19.93M | 7.00M |
| Financing Cash Flow | 115.23M | 150.99M | 158.21M | 53.09M | - | 30.07M | 406.00K | 95.14M | -3.12M |
| Capital Expenditure | -1.96M | -24.94M | -21.83M | -3.73M | -157.00K | -2.48M | -5.00K | -75.00K | - |
| Free Cash Flow | 4.52M | -67.50M | -113.19M | -98.06M | - | -13.44M | -18.68M | -67.79M | -33.54M |
| Net Change in Cash | - | - | - | - | - | 16.65M | -18.28M | 47.35M | -29.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -1,126.0% | -6,599.2% | -4,821.0% | -282.4% | -589.8% | 725.5% | - | 31.5% |
| Net Margin % | - | -1,044.3% | -6,237.5% | -4,762.9% | -281.9% | -643.6% | 808.0% | - | 55.5% |
| ROE % | 76.0% | -28.3% | -40.2% | -65.7% | - | 32.8% | 29.4% | -841.1% | 71.0% |
| ROCE % | -23.0% | -25.3% | -36.9% | -54.0% | - | -1,003.5% | -146.5% | -87.1% | 33.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 13.87% | 4.13M | $43.51M |
| 2 | Boxer Capital Management, LLC | 10.58% | 3.15M | $33.19M |
| 3 | Atlas Venture Life Science Advisors, LLC | 9.13% | 2.72M | $28.64M |
| 4 | BVF Inc. | 7.89% | 2.35M | $24.77M |
| 5 | RA Capital Management, L.P. | 7.84% | 2.33M | $24.58M |
| 6 | Point72 Asset Management, L.P. | 3.94% | 1.17M | $12.37M |
| 7 | Opaleye Management Inc. | 3.13% | 931.00K | $9.81M |
| 8 | Logos Global Management LP | 2.69% | 800.00K | $8.43M |
| 9 | Summittx Capital, L.P. | 2.46% | 733.77K | $7.73M |
| 10 | Vanguard Capital Management LLC | 1.74% | 518.80K | $5.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QTTB
QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE5kclFUOHdYekYwb3I4UWhlYTI5NnhWTHFEOTI3anFvRnlSUXVHS1ZjZzllUndLNHd0VkNobEYzZHY2bWdzSFY1U0ZR?oc=5" target="_blank">QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading I…
(QTTB) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdEI3dVdOcXFmcWNDNXpqbzQ3emdkdlVmdzlablFmRDA4NFdvOVZGN0NBbUMxU0dHOXhGbnJueTc1ekcyWHJBZjRUbU1IZ1QtLXFwa2xoRzQtT0JBRXVaWGtDd3YzNWUyZXpKaWc5bGJVeHdmZmh6MEd2X1NKWnZXOHJzRHU0NUpjVXJtSm…
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQS1doc2lNUk9EWjktN01aSkhKanlCUXRkelgyU01vcnpuQkhKX0Z2cHNieUg2QnRHaTV5ZFc2QXZlZXpnUzQ3cElmV3FmUU9NSkw4MHpxVmRxaWt4U3M0ZFQxZGtFT0dkMzhDZ2VCU2swb2RZYS1HTlJFWEtFcWRHT3ZnZjB1b0o3S1AwSE…
Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOVkkySzRZa1ViWlJPNktHSlFSVDA0azM4RV82bnpheDdTdk5PYkVBazhLOUFnXzV3aUZmenA5M1d2RjBFcEE0emhZc0JZLXM0UFMxVDlmZnNzekU5NlA5NDU0eU1GLXhjS3psazdpTzJHdFpjUFItcEQ0Z21sQ09naHhTbU9tbnozQWhhdG…
Q32 Bio Inc. Stock (QTTB) Opinions on Massive Price Surge - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQYmF6Y0lRRXI2RUxaV1k5RVp5bmUwTEFwWjRyT09NWGhES05JdUlJVk1RM2V5dGJaN3lDd1Rqb29WMGQ4Q3FaSlN0THZVdnJyVGJMQW9OaWpHWXdjakQ3NVFPRFQ4WEZOc2hzQVlNaUZ3bkwwNzh1a20zcGdwN25DNDJVYmtRb3k3ZldLUk…
Q32 Bio Announces $55 Million Private Placement Financing - PR Newswire
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQSGVtaGRGMG9FbE5YMEpyVzR1MjM3ODBRcFpSdEZ0M2lXX0FFeExRcTA5V3p6Vy13eUphRFRtVGRacFJPellocTVVM0VWdjU1bEF1QnRWeGttU0tUMGV3ZXlyTkdfd29QQ25HcHM2SmZCU0ZmMHM3TUIweF92XzkzeTNBdl9WYjRScU5NeW…
QTTB — Frequently Asked Questions
What is the current share price of Q32 Bio Inc. (QTTB)?
As of 2026-09-19 21:16 PDT, Q32 Bio Inc. (QTTB) trades at $11.69 on NasdaqCM. Its 52-week range is $1.66 to $21.38.
What is the market capitalisation of QTTB?
Q32 Bio Inc. (QTTB) has a market capitalisation of $348.01M on NasdaqCM.
What is the P/E ratio of QTTB?
QTTB trades at a trailing price-to-earnings (P/E) ratio of 3.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.36.
What is the return on equity (ROE) of QTTB?
QTTB has a return on equity (ROE) of 72.14%. Its return on capital employed (ROCE) is 33.52%.
Is QTTB a good stock to buy?
This page provides a data-driven analysis of Q32 Bio Inc. (QTTB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.